Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.

Gustbée, Emma ; Tryggvadottir, Helga LU ; Markkula, Andrea LU ; Simonsson, Maria LU ; Nodin, Björn LU ; Jirström, Karin LU orcid ; Rose, Carsten LU ; Ingvar, Christian LU ; Borgquist, Signe LU and Jernström, Helena LU (2015) In BMC Clinical Pathology 15.
Abstract
The mevalonate pathway synthetizes cholesterol, steroid hormones, and non-steriod isoprenoids necessary for cell survival. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment. HMGCR expression in breast tumors has recently been proposed to hold prognostic and treatment-predictive information. This study aimed to investigate whether HMGCR expression in breast cancer patients was associated with patient and tumor characteristics and disease-free survival (DFS).
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
BMC Clinical Pathology
volume
15
article number
8
publisher
BioMed Central (BMC)
external identifiers
  • pmid:26109908
  • pmid:26109908
  • scopus:84929991987
  • wos:000360473100001
ISSN
1472-6890
DOI
10.1186/s12907-015-0008-2
language
English
LU publication?
yes
id
6fa86209-d806-44ce-bce0-6277f43f3b19 (old id 7477960)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26109908?dopt=Abstract
date added to LUP
2016-04-01 12:58:54
date last changed
2024-01-09 04:54:16
@article{6fa86209-d806-44ce-bce0-6277f43f3b19,
  abstract     = {{The mevalonate pathway synthetizes cholesterol, steroid hormones, and non-steriod isoprenoids necessary for cell survival. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment. HMGCR expression in breast tumors has recently been proposed to hold prognostic and treatment-predictive information. This study aimed to investigate whether HMGCR expression in breast cancer patients was associated with patient and tumor characteristics and disease-free survival (DFS).}},
  author       = {{Gustbée, Emma and Tryggvadottir, Helga and Markkula, Andrea and Simonsson, Maria and Nodin, Björn and Jirström, Karin and Rose, Carsten and Ingvar, Christian and Borgquist, Signe and Jernström, Helena}},
  issn         = {{1472-6890}},
  language     = {{eng}},
  publisher    = {{BioMed Central (BMC)}},
  series       = {{BMC Clinical Pathology}},
  title        = {{Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.}},
  url          = {{https://lup.lub.lu.se/search/files/3086931/8841235}},
  doi          = {{10.1186/s12907-015-0008-2}},
  volume       = {{15}},
  year         = {{2015}},
}